1. Home /
    2. Altai Protocol Library /
  2. New Indication: Rucaparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Rucaparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

New Indication: Rucaparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study:
  • Randomized, controlled, phase 3 trial (TRITON-3)
  • Metastatic, castration-resistant prostate cancer with a BRCA1, BRCA2, or ATM alteration and who had disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI)
  • Rucaparib (n=270) vs. SOC (n=135)
Efficacy:
  • In BRCA1/2 mutant subgroup: mrPFS: 11.2 vs. 6.4 mos, p<0.001
  • In ITT group: mrPFS: 10.2 vs. 6.4 mos, p=<0.001
Safety:
  • Any grade: fatigue (61.% vs. 63%), nausea (50% vs 19%), anemia (47% vs 18%), diarrhea (31% vs. 28%)
  • Grade≥3 AEs: anemia (24% vs. 1%), fatigue (7% vs. 9%).

N Engl J Med 2023; 388:719-732

Fizazi K. et al. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

http://doi.org/10.1056/NEJMoa2214676

Reviewed by Elvin CHALABİYEV, MD on APR 17, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More